Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

ValiRx (VAL) Share Price

Price 0.675p on 20-06-2025 at 18:20:08
Change 0.125p 22.73%
Buy 0.75p
Sell 0.60p
Buy / Sell VAL Shares
Last Trade: Buy 250,000.00 at 0.75p
Day's Volume: 43,242,031
Last Close: 0.675p
Open: 0.75p
ISIN: GB00BLH13C52
Day's Range 0.65p - 0.80p
52wk Range: 0.39p - 3.30p
Market Capitalisation: £3m
VWAP: 0.712231p
Shares in Issue: 374m

ValiRx (VAL) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 250,000 0.75p Ordinary
16:40:22 - 20-Jun-25
Buy* 395,000 0.715p Suspected BUY Trade
16:21:36 - 20-Jun-25
Buy* 50,000 0.71p Suspected BUY Trade
16:16:05 - 20-Jun-25
Buy* 100,000 0.72p Ordinary
16:15:51 - 20-Jun-25
Buy* 50,000 0.71p Suspected BUY Trade
16:14:47 - 20-Jun-25
Buy* 150,000 0.71p Suspected BUY Trade
16:14:30 - 20-Jun-25
Buy* 5,000 0.72p Ordinary
15:59:28 - 20-Jun-25
Buy* 68,500 0.73p Ordinary
15:51:16 - 20-Jun-25
Sell* 15,625 0.645p Ordinary
15:39:53 - 20-Jun-25
Unknown* 36,624 0.675p Ordinary
15:36:58 - 20-Jun-25
See more ValiRx trades

ValiRx (VAL) Share Price History

Time period:
to
Date Open High Low Close Volume
20th Jun 2025 (Fri) 0.75 0.80 0.65 0.675 43,242,031
19th Jun 2025 (Thu) 0.475 0.55 0.475 0.55 4,674,161
18th Jun 2025 (Wed) 0.475 0.475 0.475 0.475 316,054
17th Jun 2025 (Tue) 0.475 0.475 0.475 0.475 27,398
16th Jun 2025 (Mon) 0.475 0.475 0.475 0.475 0
13th Jun 2025 (Fri) 0.45 0.475 0.45 0.475 1,251,153
12th Jun 2025 (Thu) 0.45 0.45 0.45 0.45 2,733,484
11th Jun 2025 (Wed) 0.45 0.45 0.45 0.45 287,794
10th Jun 2025 (Tue) 0.45 0.45 0.45 0.45 968,019
9th Jun 2025 (Mon) 0.45 0.45 0.45 0.45 141,027
6th Jun 2025 (Fri) 0.475 0.475 0.40 0.45 7,364,594
5th Jun 2025 (Thu) 0.475 0.50 0.475 0.50 2,521,404
4th Jun 2025 (Wed) 0.475 0.475 0.475 0.475 1,132,335
3rd Jun 2025 (Tue) 0.55 0.55 0.475 0.475 1,185,451
2nd Jun 2025 (Mon) 0.55 0.55 0.55 0.55 151,865
30th May 2025 (Fri) 0.55 0.55 0.55 0.55 496,599
29th May 2025 (Thu) 0.55 0.55 0.55 0.55 593,540
28th May 2025 (Wed) 0.55 0.55 0.55 0.55 285,407
27th May 2025 (Tue) 0.55 0.55 0.55 0.55 358,243
26th May 2025 (Mon) 0.5075 0.5075 0.5075 0.5075 0
23rd May 2025 (Fri) 0.55 0.55 0.55 0.55 4,025,787
22nd May 2025 (Thu) 0.55 0.55 0.55 0.55 80,564
See more ValiRx price history

ValiRx (VAL) Regulatory News

Date Source Headline
20th Jun 2025 7:00 am RNS Ambrose Exercise Option on VAL401
9th Jun 2025 10:57 am RNS ValiRx Investor Webinar
6th Jun 2025 10:54 am RNS Holding(s) in Company
6th Jun 2025 7:00 am RNS Final Results & Notice of AGM
3rd Jun 2025 7:00 am RNS New Evaluation and Material Transfer Agreement
20th May 2025 1:25 pm RNS Holding(s) in Company
12th May 2025 7:00 am RNS Inaphaea Deal Extension With Dominion
30th Apr 2025 7:00 am RNS Commercial Update
3rd Apr 2025 7:00 am RNS Termination of Letter of Intent with TheoremRx
27th Mar 2025 7:00 am RNS Directorate Changes and new Advisory Board
See more ValiRx regulatory news

ValiRx (VAL) Share News

CORRECT: Stocks rise, UK data paints "gloomy" picture

20th Jun 2025 14:26

(Corrects the name of the AJ Bell analyst quoted.) Read More

LONDON MARKET MIDDAY: Stocks rise, UK data paints "gloomy" picture

20th Jun 2025 12:04

(Alliance News) - Stock prices in London were higher at midday on Friday, amid a slight lull in tensions over the Israel-Iran conflict after US President Donald Trump gave himself two weeks to decide whether to join Israel's strikes on Iran. Read More

ValiRx signs licence with Ambrose worth GBP16 million plus royalties

20th Jun 2025 10:41

(Alliance News) - ValiRx PLC shares surged on Friday as it said Ambrose Healthcare Ltd has exercised its option to licence its VAL401 asset for GBP16 million plus royalties. Read More

ValiRx subsidiary enters evaluation agreement with Omios Biologics

3rd Jun 2025 15:31

(Alliance News) - ValiRx PLC on Tuesday said subsidiary Cytolytix Ltd has entered an evaluation and material transfer agreement with California-based biotechnology firm Omios Biologics. Read More

IN BRIEF: ValiRx extends agreement with Dominion Biotech

12th May 2025 21:40

ValiRx PLC - Essex-based life sciences company focusing on early-stage cancer therapeutics and women's health - signs an extension to the evaluation and commercial use agreement with UK based Dominion Biotech Ltd announced on April 30. Under the extension, Inaphaea will share access to results from a proprietary screen of around 3000 Food & Drug Administration approved drugs generated in a panel of patient derived cells. The drugs are approved for non-cancer applications and Dominion will mine the data for potential cancer applications, carrying out routine analysis to validate the most promising candidates at its own expense; the parties will agree and share any additional in-depth studies if required. The results of the analysis will be jointly owned, and both parties will share equally all costs associated with filing, prosecution and maintenance of any arising patents for any repurposed drugs. The parties will work together to commercialise any new assets either to the owner of the original drug compounds or alternative companies interested in the repurposed assets. All revenue generated will be equally shared after costs. Read More

See more ValiRx news
FTSE 100 Latest
Value8,774.65
Change-17.15

Login to your account

Forgot Password?

Not Registered